Evidence map›Paper›PMID 35060356›Full record

Observational studyESC heart failure2022

Eyes on amyloidosis: microvascular retinal dysfunction in cardiac amyloidosis.

Emanuel Zampiccoli, Jens Barthelmes, Leonie Kreysing, Matthias P Nägele, Delia Nebunu, Thomas Haider, Arnold von Eckardstein, Bernhard Gerber, Rahel Schwotzer, Frank Ruschitzka and 2 more

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in ESC heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Emanuel ZampiccoliDepartment of Cardiology, University Hospital Zurich, University of Zurich, Raemistrasse 100, Zurich, 8091, Switzerland.
Jens BarthelmesDepartment of Cardiology, University Hospital Zurich, University of Zurich, Raemistrasse 100, Zurich, 8091, Switzerland.ORCID 0000-0003-1010-3436
Leonie KreysingDepartment of Cardiology, University Hospital Zurich, University of Zurich, Raemistrasse 100, Zurich, 8091, Switzerland.
Matthias P NägeleDepartment of Cardiology, University Hospital Zurich, University of Zurich, Raemistrasse 100, Zurich, 8091, Switzerland.
Delia NebunuDepartment of Cardiology, University Hospital Zurich, University of Zurich, Raemistrasse 100, Zurich, 8091, Switzerland.ORCID 0000-0001-9226-4983
Thomas HaiderDepartment of Cardiology, University Hospital Zurich, University of Zurich, Raemistrasse 100, Zurich, 8091, Switzerland.ORCID 0000-0002-3048-4662
Arnold von EckardsteinDepartment of Clinical Chemistry, University Hospital Zurich, University of Zurich, Raemistrasse 100, Zurich, 8091, Switzerland.ORCID 0000-0002-1666-2266
Bernhard GerberClinic of Haematology, Oncology Institute of Southern Switzerland, Piazza Indipendenza 2, Bellinzona, 6500, Switzerland.
Rahel SchwotzerDepartment of Medical Oncology and Haematology, University Hospital Zurich, Raemistrasse 100, Zurich, 8091, Switzerland.
Frank RuschitzkaDepartment of Cardiology, University Hospital Zurich, University of Zurich, Raemistrasse 100, Zurich, 8091, Switzerland.ORCID 0000-0001-5972-0596
Isabella SudanoDepartment of Cardiology, University Hospital Zurich, University of Zurich, Raemistrasse 100, Zurich, 8091, Switzerland.ORCID 0000-0001-8197-8892
Andreas J FlammerDepartment of Cardiology, University Hospital Zurich, University of Zurich, Raemistrasse 100, Zurich, 8091, Switzerland.ORCID 0000-0002-1373-0630
University of Zurich · CHInstitute of Oncology Research · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsCardiac involvement in systemic amyloidosis is a marker of particularly poor prognosis. Cardiac amyloidosis (CA) is characterized by extracellular amyloid deposits inducing heart failure and symptoms of cardiac microvascular disease. While amyloid deposition is most common in the myocardium but also seen in pericardium and endocardium, atria, and vasculature, the role of (micro-)vascular dysfunction in CA pathophysiology remains still elusive. Because vascular function is associated with cardiovascular risk and severity of heart failure and represents a potential therapeutic target in CA, the present study investigated retinal vascular function, flow-mediated dilatation (FMD), and pulse-wave analysis and velocity (PWA/PWV) in patients with CA. METHODS AND

resultsFlicker-induced arterial dilatation (FIDa) was measured using dynamic retinal vessel analysis additionally to FMD and PWA/PWV. Thirty-three patients with CA [age 67 years [interquartile range, IQR, 62, 74], 14 with amyloid light-chain (AL) and 19 with transthyretin (ATTR) amyloidosis] were prospectively included in this cross-sectional, observational study and 70 healthy individuals (age 53 years [IQR 39, 67]) served as control. Potential confounders were balanced using entropy balancing propensity score analysis [inverse probability weighting (IPW)]. FIDa was reduced in CA patients (1.52 ± 1.73% vs. 3.09 ± 1.96%, P < 0.001, after IPW). While PWV was increased (8.74 ± 2.34 m/s vs. 7.49 ± 1.65 m/s, P = 0.018, after IPW), no difference in FMD was observed. FIDa was significantly associated with prognostic biomarkers of CA [estimated glomerular filtration rate (r = 0.33; P < 0.001), log-scaled troponin T (r = -0.49; P < 0.001), and N-terminal pro-B-type natriuretic peptide (r = -0.51; P < 0.001)].

conclusionsRetinal vascular function is impaired, associated with cardiac and renal biomarkers of CA severity, and may represent a potential therapeutic target in patients with amyloidosis.

Indexed as

AmyloidosisHeart DiseasesHeart FailureImmunoglobulin Light-chain AmyloidosisAgedCross-Sectional StudiesHumansMiddle AgedCardiac amyloidosisEndotheliumHeart failureRetinal vessel analysisVascular dysfunction

Identifiers

PMID35060356
PMCPMC8934987
OpenAlexW4205274749

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.